Sitemap

Human Health

» Clinical Studies

» For patients

» Human Health

Animal Health

» Animal Health

» Clinical Studies

» For companion animal owners

» For veterinarians

Management

» Annette Ljungmark (born 1950)

» Hans Sundin (born 1945)

» Julian Aleksov (born 1965)

» Weine Nejdemo (born 1948)

Department Directors

» Amir Tatarevic

» Annette Ljungmark

» Dzianis Babrou

» Henrik von Euler

» Malin Schenerfelt

» Margareta Eriksson

» Maria Lundén

» Maria Nylander

» Weine Nejdemo

Board of directors

» Bo Cederstrand (born 1939)

» Horst Domdey (born 1951)

» Jan Lundberg (born 1946)

» Joel Citron (born 1962)

» Julian Aleksov (born 1965)

» Martin Nicklasson (born 1955)

Annual General Meeting

» Summary of the Annual General Meeting 2006

» Summary of the Annual General Meeting 2007

» Summary of the Annual General Meeting 2008

» Summary of the Annual General Meeting 2010

» Summary of the Annual General Meeting 2011

Corporate governance

» Annual General Meetings

» Articles of Association

» Board of Directors

» Chairman of the Board

» Corporate Governance

» Corporate Governance reports

» Department Directors

» Nomination committee

» Option program

» Work plan for the Board of Directors

The share

» Shareholders

Investor relations

» Current reports

» Disclaimer issue prospectus

» Investor Relations

About Oasmia

» About Oasmia

» Organization

» Research & development

» Vision & goals

Media contact

» Media contact

Job vacancies

» Would you like to work with us?

Contact us

» Contact information

Pages

Press releases

» A big step for Oasmia in Barcelona

» Abbott and Oasmia Pharmaceutical Announce Exclusive Distribution Agreement for Paccal® Vet, a New Chemotherapeutic Agent for Dogs

» American veterinarians see the future in drug candidate Paclical® Vet

» Björn Björnsson new Chairman of the Board of Oasmia Pharmaceutical AB

» Björn Björnsson nominated as new Member of the Board in Oasmia Pharmaceutical AB

» Clinical study with Doxophos® Vet approved

» Communiqué from Annual General Meeting

» Communiqué from Annual General Meeting 2010

» Communiqué from Annual General Meeting 2011

» Communiqué from Extraordinary General Meeting

» Convincing results for Oasmia's Cancer Candidate Paclical® Vet

» Directed new share issue successfully completed – nxt2b new major shareholder

» EMEA final advice for start of Oasmia's Paclical® Phase III program

» Enrolment complete in Phase III study with Paclical®

» FDA grants Oasmia Pharmaceutical Expedited Review Status (ERS) for Paclical® Vet

» FDA grants Paccal® Vet Minor Use designation for mammary tumors

» FDA grants Paccal® Vet Minor Use designation for squamous cell carcinoma

» Great interest for Oasmia in Budapest

» Interim report May 1 - July 31 2009

» Interim report May 1 - July 31 2010

» Interim report May 1 - July 31 2011

» Interim report May 1 - Oct 31 2010

» Interim report May 1 - October 31 2011

» Interim report May 1 2010 - Jan. 31 2011

» Interim report May 1, 2009 - January 31, 2010

» Interim report May 2008 - January 2009

» Last patient out (LPO) for Paccal® Vet Phase III study

» New drug for treatment of cancer in dog

» Notice of Annual General Meeting

» Notice of the Annual General Meeting 2011

» Oasmia and Orion Corporation jointly end Paclical® agreement

» Oasmia announces launch of private placement of new shares

» Oasmia appoints E. Öhman J:or Fondkommission AB as market maker and financial advisor as well as forwards the publication of the interim report

» Oasmia changes marketplace

» Oasmia changes report publication date

» Oasmia closes agreement with Nippon Zenyaku Kogyo.

» OASMIA CONFIRMS ORPHAN DRUG DESIGNATION FOR OAS-PAC-100 (PACLITAXEL MICELLAR)

» Oasmia enters new important license agreement for Paclical® Vet with Orion Corporation

» Oasmia expands license agreement for Paclical® Vet to include European-wide rights

» Oasmia initiates clinical studies with the new pharmaceutical candidate Doxophos® Vet for treatment of cancer in dogs.

» Oasmia is admitted to trading on NASDAQ OMX Stockholm

» OASMIA OBTAINS ORPHAN DRUG DESIGNATION FOR OAS-PAC-100 (PACLITAXEL MICELLAR)

» OASMIA PHARMACEUTICAL AB (publ.) CALL TO EXTRAORDINARY GENERAL MEETING

» OASMIA PHARMACEUTICAL AB (publ.) Notice of Annual General Meeting 2009

» Oasmia Pharmaceutical AB announces a fully committed and underwritten rights issue of SEK 239 million

» Oasmia Pharmaceutical AB announces agreement with Baxter Oncology GmbH for large scale commercial manufacturing

» Oasmia Pharmaceutical AB, Sweden and Medison Pharma, Israel announce license and distribution agreement for Paclical® in Israel and Turkey

» Oasmia Pharmaceutical AB, Sweden has applied for listing at Frankfurt Stock Exchange

» Oasmia Pharmaceutical AB, Uppsala, Sweden, carries out private placement

» Oasmia Pharmaceutical AB:s listing on the Frankfurt Stock Exchange approved

» Oasmia Pharmaceutical aims for worldwide registration with a pivotal study on Paccal® Vet

» Oasmia Pharmaceutical announces licensing agreement with Orion Corporation regarding new innovative ovarian cancer drug candidate, Paclical®.

» Oasmia Pharmaceutical appoints Remium as liquidity provider and financial advisor

» Oasmia Pharmaceutical begins the centralized approval procedure for Paccal® Vet with the EMA

» Oasmia Pharmaceutical candidate Paclical® shows promising results in patients with severe cancer.

» Oasmia Pharmaceutical completes rights issue of SEK 238.7 million

» Oasmia Pharmaceutical, Sweden, announces distribution agreement with Abbott Laboratories for Paccal® Vet on the US and Canadian veterinary market.

» Oasmia Pharmaceutical's international multicentre Phase III study on ovarian cancer generates great interest across Europe

» Oasmia presents Paclical® Vet in Budapest

» Oasmia presents Phase III results for Paclical® Vet in Copenhagen

» Oasmia proposes new share issue

» Oasmia publishes Interim Report for May - Oct

» Oasmia publishes Listing Prospectus

» Oasmia publishes the annual report for the fiscal year 2010/2011

» Oasmia S.A. offers background and facts in response to accusations in the media

» Oasmia S.A.’s commitment to subscribe for shares in Oasmia Pharmaceutical AB’s (publ) rights issue

» Oasmia Successfully Concludes Enrolment for Pivotal Study of Mast Cell Tumors in Dogs

» Oasmia Sweden enters into SEK 75 million Standby Equity Distribution Agreement with U.S.-based YA Global Master SPV Ltd.

» Oasmia to NGM Equity

» Oasmia: Clinical study shows good tolerance for Doxophos® Vet

» Oasmia: FDA grants Paccal® Vet Minor Use status

» Oasmia: FDA grants Paclical® Orphan Drug Designation for ovarian cancer in the USA

» Oasmia’s rights issue fully subscribed

» Oasmia's cancer drug one step closer the American market

» Paccal Vet´s Phase III study submitted to FDA for evaluation of clinical efficacy and safety

» Positive Phase III result from the interim analysis of the study in ovarian cancer with Paclical®

» Preliminary analysis indicates that Oasmia's product candidate Paccal® Vet met primary endpoint in Phase III study in dogs with mastocytoma

» Prospectus regarding Oasmia Pharmaceutical's rights issue is now available

» Publication of change in the total number of shares and votes in Oasmia

» Publication of change in the total number of shares and votes in Oasmia

» Solid scientific evidence for Oasmia product candidate Paccal® Vet

» Status – listing of Oasmia

» The Nomination Committee’s proposal regarding Board members in Oasmia Pharmaceutical AB

» The Oasmia Pharmaceutical share is now traded on NASDAQ OMX Stockholm

» The prospectus for Oasmia's new share issue 2009 is now available

» Ticker: Clarification regarding Oasmia SA

» Two thirds of the patients enrolled in the Paclical® Phase III study

» Unique results for cancer drug presented in Cambridge

» Very good clinical results for Paclical®

» Year-end report May 1 2009 - April 30 2010

» Year-end report May 1 2010 - April 30 2011

Latest News (displayed on frontpage)

» Analysis from ECOFIN Global Consulting

» Dr. Kalliwoda Research GmbH presents a new analysis of Oasmia Pharmaceutical AB

bottom